United States-based Conformal Medical Inc has named George Fazio as its new director, it was reported on Thursday.
Presently, Fazio is the president and chief executive officer of Corvia Medical. He has over three decades of executive experience in the cardiovascular space. He has served in various senior leadership positions with St Jude Medical, including serving as president of the United States and EMEA regions, and both the cardiovascular and cardiac surgery businesses. He also held the position of president of Health Care Services.
Andy Levine, co-founder and chief executive officer of Conformal Medical, said, 'We are very pleased to have George join Conformal's board of directors at this important time as we embark on our US IDE trial. We are confident that his strategic business insights, extensive knowledge in the cardiovascular market, and experience as an executive of a private medical device company will add tremendous value as we advance our technology through upcoming clinical and regulatory milestones.'
Bayer and Broad Institute extend cardiovascular research alliance to advance precision therapies
CirCode Biomed's IND application for HM2002 receives FDA clearance
CeleCor Therapeutics completes Phase 3 trial of new anti-platelet agent for heart attack
Sarepta receives UK approval to continue dosing in ELEVIDYS ENVISION study
Ionis reports positive Phase 3 results for olezarsen in moderate hypertriglyceridemia
Nordic Bioscience launches new Endotrophin assay
AbbVie and ADARx Pharmaceuticals partner on next-generation siRNA therapies
Otsuka's leukaemia drug ponatinib launched on Fangzhou platform
FDA accepts Novo Nordisk's filing application for oral semaglutide 25 mg
Avacta Therapeutics reports positive Phase 1 data for lead candidate
Innovent's limertinib receives Chinese regulatory approval for first-line treatment of lung cancer
Primo Biotechnology's Taoyuan facility granted PIC/S GMP Certification
Renibus Therapeutics completes RBT-1 Phase 3 clinical trial enrolment